Literature DB >> 18250992

Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.

Bishnuhari Paudyal1, Noboru Oriuchi, Pramila Paudyal, Yoshito Tsushima, Tetsuya Higuchi, Mitsuyuki Miyakubo, Tomohiro Ishikita, Takashi Nakajima, Keigo Endo.   

Abstract

We report the results of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and immunohistochemical staining of glucose transporter 1 (Glut-1) and hexokinase II (HK-II) in patients with hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) to observe the variation in (18)F-FDG uptake and variation in expression of Glut-1 and HK-II in these hepatic tumors. In the case of HCC, moderate (18)F-FDG uptake and strong expression of HK-II were detected, whereas Glut-1 was not expressed. Conversely, CCC showed high (18)F-FDG uptake and increased expression of Glut-1 but HK-II was not expressed. The variation in the (18)F-FDG uptake and expression of Glut 1 and HK-II in HCC and CCC might be owing to the difference in origin and the different mechanisms involved in glucose uptake, rate of glucose transporters, and hexokinase activity involved in the glycolytic pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250992     DOI: 10.1007/s12149-007-0076-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  12 in total

1.  Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Kunihiko Izuishi; Yuka Yamamoto; Takanori Sano; Ryusuke Takebayashi; Yoshihiro Nishiyama; Hirohito Mori; Tsutomu Masaki; Asahiro Morishita; Yasuyuki Suzuki
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

2.  Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT.

Authors:  Wei Guo; Yizhen Pang; Lanlin Yao; Liang Zhao; Chunlei Fan; Jingpeng Ke; Ping Guo; Bing Hao; Hao Fu; Chengrong Xie; Qin Lin; Hua Wu; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-11       Impact factor: 9.236

3.  Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings.

Authors:  Haojun Chen; Liang Zhao; Dan Ruan; Yizhen Pang; Bing Hao; Yaqing Dai; Xiurong Wu; Wei Guo; Chunlei Fan; Jingxun Wu; Weipeng Huang; Qin Lin; Long Sun; Hua Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-25       Impact factor: 9.236

4.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

5.  68Ga-FAPI-46 PET/MR Detects Recurrent Cholangiocarcinoma and Intraductal Papillary Mucinous Neoplasm in a Patient Showing Increasing CEA with Negative 18F-FDG PET/CT and Conventional CT.

Authors:  Dheeratama Siripongsatian; Chetsadaporn Promteangtrong; Anchisa Kunawudhi; Peerapon Kiatkittikul; Chanisa Chotipanich
Journal:  Nucl Med Mol Imaging       Date:  2021-08-23

Review 6.  PET and MR imaging: the odd couple or a match made in heaven?

Authors:  Ciprian Catana; Alexander R Guimaraes; Bruce R Rosen
Journal:  J Nucl Med       Date:  2013-03-14       Impact factor: 10.057

7.  Perfusion CT and PET with 18F-FDG and 18F-FCh in the complex diagnosis of hepatocellular carcinoma.

Authors:  P E Tulin; M B Dolgushin; A A Odzharova; A I Mikhaylov; B M Medvedeva; S V Shiryaev; B I Dolgushin
Journal:  Eur J Hybrid Imaging       Date:  2017-12-01

8.  [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer.

Authors:  Ryusuke Takebayashi; Kunihiko Izuishi; Yuka Yamamoto; Reiko Kameyama; Hirohito Mori; Tsutomu Masaki; Yasuyuki Suzuki
Journal:  J Exp Clin Cancer Res       Date:  2013-05-29

Review 9.  18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Nobuyuki Kawai; Keisuke Miyake; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Biomed Res Int       Date:  2013-06-17       Impact factor: 3.411

10.  Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma.

Authors:  Hyun Gyu Lee; Hyemi Kim; Taekwon Son; Youngtae Jeong; Seung Up Kim; Seung Myung Dong; Young Nyun Park; Jong Doo Lee; Jae Myun Lee; Jeon Han Park
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.